Home LiteratureArticle Details
PMID: 11264363 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Journal of virology ·Vol. 75 ·No. 8 ·2001-04-00 ·Pages 3740-52

Nikiforow S, Bottomly K, Miller G

Abstract

In immunodeficient hosts, Epstein-Barr virus (EBV) often induces extensive B-cell lymphoproliferative disease and lymphoma. Without effective in vitro immune surveillance, B cells infected by the virus readily form immortalized cell lines. In the regression assay, memory T cells inhibit the formation of foci of EBV-transformed B cells that follows recent in vitro infection by EBV. No one has yet addressed which T cell regulates the early proliferative phase of B cells newly infected by EBV. Using new quantitative methods, we analyzed T-cell surveillance of EBV-mediated B-cell proliferation. We found that CD4+ T cells play a significant role in limiting proliferation of newly infected, activated CD23+ B cells. In the absence of T cells, EBV-infected CD23+ B cells divided rapidly during the first 3 weeks after infection. Removal of CD4+ but not CD8+ T cells also abrogated immune control. Purified CD4+ T cells eliminated outgrowth when added to EBV-infected B cells. Thus, unlike the killing of EBV-infected lymphoblastoid cell lines, in which CD8+ cytolytic T cells play an essential role, prevention of early-phase EBV-induced B-cell proliferation requires CD4+ effector T cells.

MeSH Terms
Adult B-Lymphocytes/cytology,immunology,metabolism,virology CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology Cell Division/drug effects Cell Size Cells, Cultured Epstein-Barr Virus Infections/immunology,virology Epstein-Barr Virus Nuclear Antigens/metabolism Flow Cytometry Herpesvirus 4, Human/physiology Humans Immunologic Memory/immunology Lymphocyte Count Receptors, IgE/metabolism Serology T-Lymphocyte Subsets/immunology Tacrolimus/pharmacology
Chemicals
Epstein-Barr Virus Nuclear Antigens Receptors, IgE Tacrolimus
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Nikiforow S
Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Bottomly K
Miller G
References (69)
69 references, click to expand
  1. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
    Acta Virol. 1998 Nov;42(5):307-13 PMID: 10358731
  2. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
    Cell Immunol. 1999 Aug 1;195(2):81-8 PMID: 10448007
  3. Epstein-Barr viral nuclear antigen (EBNA) in tumor cell imprints of experimental lymphoma of marmosets.
    Trans Assoc Am Physicians. 1974;87:205-18 PMID: 4376291
  4. Immunofluorescence and anti-complement immunofluorescence absorption tests for quantitation of Epstein-Barr virus-associated antigens.
    Int J Cancer. 1975 Apr 15;15(4):566-71 PMID: 166941
  5. Assay for Epstein-Barr virus based on stimulation of DNA synthesis in mixed leukocytes from human umbilical cord blood.
    J Virol. 1975 May;15(5):1065-72 PMID: 167182
  6. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.
    J Exp Med. 1999 Aug 16;190(4):567-76 PMID: 10449527
  7. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells.
    Life Sci. 1999;65(14):1433-53 PMID: 10530796
  8. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection and interference.
    IARC Sci Publ. 1975;(11 Pt 1):395-408 PMID: 190145
  9. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.
    Int J Cancer. 1978 Dec;22(6):662-8 PMID: 214405
  10. Long-term C-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures.
    Int J Cancer. 1979 May 15;23(5):610-7 PMID: 222690
  11. Antigen-driven expansion and contraction of CD8+-activated T cells in primary EBV infection.
    J Immunol. 1999 Nov 15;163(10):5735-40 PMID: 10553106
  12. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.
    Pediatr Transplant. 1999 Nov;3(4):271-81 PMID: 10562971
  13. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
    Transplantation. 1999 Nov 27;68(10):1517-25 PMID: 10589949
  14. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.
    J Virol. 2000 Apr;74(8):3455-63 PMID: 10729118
  15. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    J Exp Med. 2000 May 15;191(10):1649-60 PMID: 10811859
  16. EBV persistence involves strict selection of latently infected B cells.
    J Immunol. 2000 Sep 15;165(6):2975-81 PMID: 10975805
  17. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads.
    J Infect Dis. 2000 Oct;182(4):1013-21 PMID: 10979894
  18. EB-virus associated serology in malignant disease: antibody levels to viral capsid antigens (VCA), membrane antigens (MA) and early antigens(EA) in patients with various neoplastic conditions.
    Int J Cancer. 1972 Mar 15;9(2):353-64 PMID: 4339412
  19. Immortalizing and nonimmortalizing laboratory strains of Epstein-Barr Virus.
    Cold Spring Harb Symp Quant Biol. 1975;39 Pt 2:773-81 PMID: 169031
  20. Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines.
    Int J Cancer. 1976 Nov 15;18(5):639-52 PMID: 62724
  21. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.
    J Immunol. 1980 Feb;124(2):745-51 PMID: 6243331
  22. HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells.
    Nature. 1980 Feb 28;283(5750):865-7 PMID: 6244495
  23. Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells.
    Cell Immunol. 1983 Mar;76(2):311-21 PMID: 6301696
  24. Characterisation of Epstein-Barr virus-specific memory T cells from the peripheral blood of seropositive individuals.
    Br J Cancer. 1983 May;47(5):681-6 PMID: 6303377
  25. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies.
    Int J Cancer. 1984 Feb 15;33(2):239-43 PMID: 6319303
  26. T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A.
    Cell Immunol. 1984 Sep;87(2):646-58 PMID: 6088089
  27. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
    J Immunol. 1985 Apr;134(4):2287-93 PMID: 2857749
  28. Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus.
    Virology. 1987 Jan;156(1):153-62 PMID: 3027963
  29. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.
    Proc Natl Acad Sci U S A. 1987 Nov;84(22):8060-4 PMID: 2825176
  30. Lymphocytes activated by the Epstein-Barr virus to produce immunoglobulin do not express CD23 or become immortalized.
    Int J Cancer. 1988 Jul 15;42(1):23-8 PMID: 2839428
  31. B cell activation and the establishment of Epstein-Barr virus latency.
    J Exp Med. 1988 Dec 1;168(6):2059-75 PMID: 2848918
  32. Soluble CD23/BLAST-2 (S-CD23/Blast-2) and its role in B cell proliferation.
    Curr Top Microbiol Immunol. 1988;141:157-64 PMID: 2975205
  33. Polyclonal proliferation of activated suppressor/cytotoxic T cells with transient depression of natural killer cell function in acute infectious mononucleosis.
    Clin Exp Immunol. 1989 Jul;77(1):71-6 PMID: 2527653
  34. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.
    J Exp Med. 1991 Jan 1;173(1):147-58 PMID: 1845872
  35. SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans.
    Int J Cancer. 1991 Feb 20;47(4):510-7 PMID: 1847355
  36. Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas.
    Cancer Res. 1991 Sep 15;51(18):4743-56 PMID: 1893369
  37. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts.
    Cancer Res. 1992 May 1;52(9):2468-77 PMID: 1314693
  38. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.
    J Virol. 1992 Jun;66(6):3715-24 PMID: 1316478
  39. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus.
    Surgery. 1992 Aug;112(2):378-86 PMID: 1322566
  40. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
    Surgery. 1993 Aug;114(2):218-25; discussion 226 PMID: 8393595
  41. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
    N Engl J Med. 1994 Apr 28;330(17):1185-91 PMID: 8093146
  42. Determination of lymphocyte division by flow cytometry.
    J Immunol Methods. 1994 May 2;171(1):131-7 PMID: 8176234
  43. Immunobiology of Epstein-Barr virus-associated lymphomas.
    Clin Immunol Immunopathol. 1994 Jun;71(3):256-9 PMID: 8200127
  44. Activity of transplanted CD8+ versus CD4+ cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice.
    Transplantation. 1994 Sep 15;58(5):629-33 PMID: 7916506
  45. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Lancet. 1995 Jan 7;345(8941):9-13 PMID: 7799740
  46. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.
    Transplantation. 1995 Feb 27;59(4):524-9 PMID: 7533344
  47. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    J Immunol. 1995 Jul 1;155(1):259-65 PMID: 7602102
  48. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?
    Bone Marrow Transplant. 1995 Apr;15(4):591-4 PMID: 7655386
  49. Simple assay for evaluation of Epstein-Barr virus specific cytotoxic T lymphocytes.
    J Immunol Methods. 1995 Aug 18;184(2):149-52 PMID: 7658018
  50. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Virology. 1995 Dec 20;214(2):633-7 PMID: 8553567
  51. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1.
    Virology. 1996 May 15;219(2):489-92 PMID: 8638417
  52. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    J Exp Med. 1996 Mar 1;183(3):1215-28 PMID: 8642263
  53. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis.
    Nat Med. 1996 Aug;2(8):906-11 PMID: 8705861
  54. The mechanism of action of cyclosporin A and FK506.
    Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S40-5 PMID: 8811062
  55. Viral pathogenesis in hu-PBL-SCID mice.
    Semin Immunol. 1996 Aug;8(4):255-62 PMID: 8883149
  56. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.
    Annu Rev Immunol. 1997;15:405-31 PMID: 9143694
  57. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.
    Immunol Rev. 1997 Jun;157:195-216 PMID: 9255631
  58. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Immunol Rev. 1997 Jun;157:217-22 PMID: 9255632
  59. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
    Immunity. 1997 Dec;7(6):791-802 PMID: 9430224
  60. Epstein-Barr virus infections in children after transplantation of the small intestine.
    Am J Surg Pathol. 1998 Mar;22(3):299-309 PMID: 9500771
  61. Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.
    J Virol. 1998 May;72(5):4352-63 PMID: 9557725
  62. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines.
    Transplantation. 1998 May 15;65(9):1248-55 PMID: 9603175
  63. Structure and functions of CD23.
    Int Rev Immunol. 1997;16(1-2):113-28 PMID: 9651788
  64. CD23/Fc epsilon RII: signaling and clinical implication.
    Int Rev Immunol. 1997;16(1-2):129-46 PMID: 9651789
  65. CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.
    Int Immunol. 1998 Aug;10(8):1149-57 PMID: 9723701
  66. Detection of a high frequency of virus-specific CD4+ T cells during acute infection with lymphocytic choriomeningitis virus.
    J Immunol. 1998 Oct 1;161(7):3215-8 PMID: 9759834
  67. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.
    Nature. 1998 Oct 1;395(6701):462-9 PMID: 9774102
  68. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
    J Immunol. 1999 Feb 1;162(3):1827-35 PMID: 9973448
  69. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Pediatr Transplant. 1999 Feb;3(1):22-6 PMID: 10359027
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2001-04-00
Pages
3740-52
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC114865
Subset
IM
Grants
NIGMS NIH HHS · GM07205 · United States
NCI NIH HHS · CA16038 · United States
NCI NIH HHS · R01 CA012055 · United States
NIGMS NIH HHS · T32 GM007205 · United States
NCI NIH HHS · P01 CA016038 · United States
NCI NIH HHS · CA12055 · United States
NCI NIH HHS · R37 CA012055 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]